Thank you for sharing!

Your article was successfully shared with the contacts you provided.

BOSTON-The biotech industry is booming in the Bay State. Large biotech firms and institutional users are driving up the demand for lab space in Massachusetts as the state continues to maintain a leadership role as one of the premier industry sites in the nation. According to a study compiled by realty advisors Richards Barry Joyce and Partners, the area has seen overall positive absorption rates in the last five quarters with absorption exceptionally strong in the Boston, Cambridge and suburban areas.

Lab space in the Boston market, which also includes Cambridge and the suburbs, stands at 12.13 million sf with 6.6 million sf in Cambridge, and 2.39 million sf in Boston with the remaining 3.1 million sf divided up among the suburbs. Of that total space, only 14.2% is available. “We’ve seen not only a steady demand for bio-focused real estate, but a proliferation of different settings,” Brendan Carroll, an analyst with the locally based advisory firm, tells GlobeSt.com.

Leading the way was the Cambridge submarket, which experienced 223,000 sf of positive absorption in the last two quarters ending March 31. Carroll says the city’s reputation as a leading educational center helped drive vacancy rates down by 3.3% to 17.1% as biotech firms continue to pursue space near Cambridge’s research epicenter.

Driven by hospitals and large institutional users, Boston saw vacancy rates drop from 1.7% to a nearly non-existent 0.1% in the last two quarters with positive absorption of 39,000 sf. The state’s suburban lab market fared well during the last two quarters as well as maturing firms looked to the suburbs for more research space. According to the study, Boston’s suburbs had 67,000 sf of positive absorption during that period which lowered vacancy rates for lab space by 2.1% to 18.9%.

In 2004, the state’s biotech firms attracted 17.8% of all US biotech venture capital investments, although the figure was about 3% lower than the 20.9 share of venture capital coming to the Bay State in 2003. Developers also are high on the state’s reputation as a leader in the biotech field. Builders have 705,000 sf of lab space in the pipeline for the Boston market, but unlike the last two years, when most of that space was speculative, almost all of that construction is now preleased.

“We’re definitely seeing a conservative stance from a developer’s standpoint,” Carroll says. Another thing that bodes well for biotech in the Bay State is the acquisition last month by BioMed Realty Trust, Inc. of seven life science properties from the Lyme Timber Co., an affiliate of Lyme Properties, Carroll notes. “The transaction between these two titans is really a validation on the highest level of the belief that biotechnology investments in Boston are strong.”

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 3 free articles* across the ALM subscription network every 30 days
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?


Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.